Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
9 hedge funds and large institutions have $158K invested in Sonnet BioTherapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
43% more capital invested
Capital invested by funds: $110K → $158K (+$47.7K)
0.1% more ownership
Funds ownership: 0.27% → 0.37% (+0.1%)
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$50.1K |
| 2 |
Renaissance Technologies
New York
|
+$42K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.56K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$177 |
| 5 |
JP Morgan Chase
New York
|
+$27 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$10.6K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$270 |
| 3 |
Morgan Stanley
New York
|
-$136 |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
-$45 |
| 5 |
Citigroup
New York
|
-$9 |
SONN Hedge Fund Activity: Q4 2023 in Review
9 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q4 2023, worth a combined $158K — up 43% from $110K a quarter earlier.
Fund positioning in SONN was balanced in Q4 2023: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $50.1K. The largest seller was UBS Group, exiting entirely with an estimated $10.6K sold.
- 9 institutional investors held Sonnet BioTherapeutics (SONN) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $158K of Sonnet BioTherapeutics stock for Q4 2023, up 43% quarter-over-quarter.
- 3 funds opened new Sonnet BioTherapeutics positions in Q4 2023 and 3 closed out, a net change of 0 holders.
- The largest Sonnet BioTherapeutics buyer in Q4 2023 was Citadel Advisors, an estimated $50.1K added.
- The largest Sonnet BioTherapeutics seller in Q4 2023 was UBS Group, an estimated $10.6K sold.
Based on aggregated 13F filings for Q4 2023.